Literature DB >> 26499781

Diagnostic and prognostic values of tissue hsa-miR-30c and hsa-miR-203 in prostate carcinoma.

Ziling Huang1,2, Long Zhang1, Xianghua Yi3, Xiaoting Yu4.   

Abstract

Prostate cancer (PCa) has become a prevalent malignant disease in males globally. Accumulating data suggested that hsa-microRNAs (miRNAs) could be potential biomarkers for tumor diagnosis due to their important roles in the cell cycle. This study investigated the diagnostic and prognostic values of hsa-miR-203 and hsa-miR-30c in PCa tissues. There were 44 pathologically confirmed PCa patients who were enrolled in this study. Tissue samples were collected from both tumor tissues and adjacent normal tissues. RNA was extracted and the expression levels of hsa-miR-203 and hsa-miR-30c in tumor and normal tissues were compared. The receiver operating characteristic (ROC) curves were plotted to evaluate the reliability of hsa-miR-203 and hsa-miR-30c in detecting PCa. All subjects in this study were followed up by 36 months, and the Kaplan-Meier method was conducted to investigate the survival status of PCa patients. The average relative expressions of hsa-miR-203 and hsa-miR-30c in tumor tissues were significantly different from those in adjacent normal tissues (P < 0.001), and the predictive power of the two hsa-miRNAs for PCa prognosis was reliable. Besides that, the average survival times of low-hsa-miR-30c and high-hsa-miR-203 groups were significantly lower than those of the corresponding groups with the log-rank P of 0.015 and 0.023, respectively. In summary, our study suggested that both hsa-miR-203 and hsa-miR-30c are potential biomarkers for detection and prognosis of PCa.

Entities:  

Keywords:  Biological markers; Diagnosis; MicroRNAs; Prognosis; Prostate cancer

Mesh:

Substances:

Year:  2015        PMID: 26499781     DOI: 10.1007/s13277-015-4262-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  44 in total

1.  Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer.

Authors:  Fulya Yaman Agaoglu; Müge Kovancilar; Yavuz Dizdar; Emin Darendeliler; Stefan Holdenrieder; Nejat Dalay; Ugur Gezer
Journal:  Tumour Biol       Date:  2011-01-28

2.  Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.

Authors:  Jason C Gonzales; Louis M Fink; Oscar B Goodman; James T Symanowski; Nicholas J Vogelzang; David C Ward
Journal:  Clin Genitourin Cancer       Date:  2011-07-01       Impact factor: 2.872

3.  Epithelial and stromal expression of miRNAs during prostate cancer progression.

Authors:  Qinghu Ren; Jiaqian Liang; Jianjun Wei; Olca Basturk; Jinhua Wang; Garrett Daniels; Lan Lin Gellert; Yirong Li; Ying Shen; Iman Osman; Jun Zhao; Jonathan Melamed; Peng Lee
Journal:  Am J Transl Res       Date:  2014-07-18       Impact factor: 4.060

4.  Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model.

Authors:  W J Catalona; A W Partin; J A Finlay; D W Chan; H G Rittenhouse; R L Wolfert; D L Woodrum
Journal:  Urology       Date:  1999-08       Impact factor: 2.649

5.  Review of the literature: PCA3 for prostate cancer risk assessment and prognostication.

Authors:  Stacy Loeb; Alan W Partin
Journal:  Rev Urol       Date:  2011

6.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.

Authors:  Xi Chen; Yi Ba; Lijia Ma; Xing Cai; Yuan Yin; Kehui Wang; Jigang Guo; Yujing Zhang; Jiangning Chen; Xing Guo; Qibin Li; Xiaoying Li; Wenjing Wang; Yan Zhang; Jin Wang; Xueyuan Jiang; Yang Xiang; Chen Xu; Pingping Zheng; Juanbin Zhang; Ruiqiang Li; Hongjie Zhang; Xiaobin Shang; Ting Gong; Guang Ning; Jun Wang; Ke Zen; Junfeng Zhang; Chen-Yu Zhang
Journal:  Cell Res       Date:  2008-10       Impact factor: 25.617

7.  MiR-215 modulates gastric cancer cell proliferation by targeting RB1.

Authors:  Yujie Deng; Zhenxia Huang; Yanjun Xu; Juan Jin; Wei Zhuo; Cheng Zhang; Xuting Zhang; Minhong Shen; Xiaoyi Yan; Liangjing Wang; Xiaojia Wang; Yibin Kang; Jianmin Si; Tianhua Zhou
Journal:  Cancer Lett       Date:  2013-08-24       Impact factor: 8.679

8.  Potential Urinary miRNA Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients.

Authors:  Taha A Haj-Ahmad; Moemen Ak Abdalla; Yousef Haj-Ahmad
Journal:  J Cancer       Date:  2014-01-29       Impact factor: 4.207

9.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

10.  Rewiring of an epithelial differentiation factor, miR-203, to inhibit human squamous cell carcinoma metastasis.

Authors:  Nathan Benaich; Samuel Woodhouse; Stephen J Goldie; Ajay Mishra; Sven R Quist; Fiona M Watt
Journal:  Cell Rep       Date:  2014-10-02       Impact factor: 9.423

View more
  5 in total

Review 1.  MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer.

Authors:  Gloria Bertoli; Claudia Cava; Isabella Castiglioni
Journal:  Int J Mol Sci       Date:  2016-03-22       Impact factor: 5.923

2.  Expression of miR-30c and miR-29b in prostate cancer and its diagnostic significance.

Authors:  Chuanan Zhu; Xiumei Hou; Jiabin Zhu; Chunxiao Jiang; Wei Wei
Journal:  Oncol Lett       Date:  2018-06-21       Impact factor: 2.967

3.  MicroRNA-21 and microRNA-30c as diagnostic biomarkers for prostate cancer: a meta-analysis.

Authors:  Hongxing Zhou; Xuming Zhu
Journal:  Cancer Manag Res       Date:  2019-03-06       Impact factor: 3.989

4.  miR‑30c suppresses prostate cancer survival by targeting the ASF/SF2 splicing factor oncoprotein.

Authors:  Ya-Qiang Huang; Xiao-Hui Ling; Run-Qiang Yuan; Zhi-Yun Chen; Sheng-Bang Yang; Hong-Xing Huang; Wei-De Zhong; Shao-Peng Qiu
Journal:  Mol Med Rep       Date:  2017-07-04       Impact factor: 2.952

5.  MicroRNA-203 predicts human survival after resection of colorectal liver metastasis.

Authors:  T Peter Kingham; Hoang C B Nguyen; Jian Zheng; Ioannis T Konstantinidis; Eran Sadot; Jinru Shia; Deborah Kuk; Steven Zhang; Leonard Saltz; Michael I D'Angelica; William R Jarnagin; Hani Goodarzi; Sohail F Tavazoie
Journal:  Oncotarget       Date:  2017-03-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.